<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01477866</url>
  </required_header>
  <id_info>
    <org_study_id>CITOGENEX CRC</org_study_id>
    <nct_id>NCT01477866</nct_id>
  </id_info>
  <brief_title>Utility Of Citogenex Administration In Patients With Colon-Rectal Cancer</brief_title>
  <acronym>CITOGENEX PA</acronym>
  <official_title>Utility Of Citogenex Administration In Patients With Colon-Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Palermo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Palermo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim of the present study is to test the efficacy and safety of CITOGENEX
      administration in patients with colon-rectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CITOGENEX is a dietary supplement of insoluble polysaccharides, of Lactobacillus Casei
      (specific type) and of Bifidobacterium Lactis (specific type). These subspecies of probiotics
      bacteria have been shown to be effective in improving the immunity. Several trials are
      currently underway, in order to evaluate the effects of probiotics as potential novel
      therapies in addition to traditional therapeutic approaches. Although probiotics do not play
      an anti-tumor action per se, these agents may significantly contribute to decrease the
      typical side effects due to traditional anti-tumor treatments, such as gastrointestinal
      symptoms, immunity deficit, as well as the alterations in the gut lymphoid tissue.

      It is therefore expected that CITOGENEX may have several significant beneficial effects in
      patients under anti-tumor treatments. In order to test this hypothesis, we will perform a
      randomized, single-blind, two-arms, prospective study in patients with colon-rectal cancer.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    the study has never started
  </why_stopped>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Colonic Neoplasms</condition>
  <arm_group>
    <arm_group_label>citogenex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>citogenex + conventional therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>conventional therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>citogenex</intervention_name>
    <description>CITOGENEX is a dietary supplement of insoluble polysaccharides, of Lactobacillus Casei (specific type) and of Bifidobacterium Lactis (specific type).</description>
    <arm_group_label>citogenex</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>conventional therapy</intervention_name>
    <description>conventional therapy for colon-rectal cancer</description>
    <arm_group_label>citogenex</arm_group_label>
    <arm_group_label>conventional therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  stage IIIa-IIIc (AJCC/TNM)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni Tomasello, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Palermo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Cappello, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Palermo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Provvidenza Damiani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Palermo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manfredi Rizzo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Palermo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Palermo</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90129</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2011</study_first_submitted>
  <study_first_submitted_qc>November 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2011</study_first_posted>
  <last_update_submitted>December 9, 2017</last_update_submitted>
  <last_update_submitted_qc>December 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Palermo</investigator_affiliation>
    <investigator_full_name>Manfredi Rizzo</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

